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Increased prevalence of oxidant stress and inflammation in pa-
tients with moderate to severe chronic kidney disease.
Background. The prevalence of increased oxidative stress
and acute-phase inflammation in patients with chronic kidney
disease (CKD) has not been thoroughly investigated.
Methods. Biomarkers of oxidative stress and acute-phase in-
flammation were measured in a cohort of 60 patients with stage
3–5 CKD compared to a healthy subject cohort. Levels of oxida-
tive stress and inflammation were also compared to estimated
glomerular filtration rate (GFR) using the Modification of Diet
in Renal Disease (MDRD) formula.
Results. All biomarkers of oxidative stress (plasma protein
carbonyl group content, plasma free F2-isoprostane content,
plasma protein reduced thiol content) and all markers of in-
flammation [C-reactive protein (CRP), interleukin-6 (IL-6)]
differed significantly between CKD patients and healthy sub-
jects. There was no significant relationship between estimated
GFR and any oxidative stress or inflammation biomarker. CRP
levels were higher in patients with known coronary vascular dis-
ease (CVD) and in patients not taking angiotensin II inhibitors.
Plasma IL-6 levels were significantly higher in patients with
known coronary vascular disease and lower in patients taking
statins. Biomarkers of oxidative stress were significantly higher
in patients with diabetes and hypercholesterolemia.
Conclusion.There is evidence of increased oxidative stress
and acute-phase inflammation in patients with stage 3–5 chronic
kidney disease compared to healthy subjects that does not
closely correlate with estimates of GFR. Among CKD patients,
inflammatory biomarkers correlate with known CVD and in-
versely correlate with the use of angiotensin II inhibitors and
statins. A further increase in oxidative stress was noted in di-
abetic and hypercholesterolemic patients. Inflammation and
oxidative stress may contribute to cardiovascular risk in CKD
patients.
Data are emerging to suggest there is a higher preva-
lence of chronic kidney disease (CKD) in the adult
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United States population than previously appreciated [1],
and that a large number of patients at earlier stages of
CKD have gone undiagnosed and undertreated [2–4]. For
example, data from the Third National Health and Nutri-
tion Examination Survey (NHANES III) suggest that the
prevalence of CKD in the United States adult population
may be as high as 11%, constituting 19.2 million individu-
als [1]. The National Kidney Foundation Kidney Disease
Outcomes Quality Initiative (K/DOQI) has recently de-
fined the stage of CKD based on the level of glomeru-
lar filtration rate (GFR). According to this classification,
Stage 3 CKD (moderately decreased GFR) is defined by
a GFR of 30–59 mL/min/1.73 m2, Stage 4 CKD (severely
decreased GFR) by a GFR of 15–29 mL/min/1.73 m2,
and Stage 5 CKD (kidney failure) by a GFR <15 mL/min/
1.73 m2 [5]. The NHANES III data also suggest that there
are more than 8 million United States adults with an es-
timated GFR less than 60 mL/min/1.73 m2, constituting
Stage 3–5 chronic kidney disease according to K/DOQI
guidelines.
Patients with Stage 3–5 CKD are at risk for progression
of kidney disease and development of end-stage renal
disease (ESRD). Moreover, these patients appear to be
at even greater risk for the development of cardiovascu-
lar disease and associated morbidity and mortality. Thus,
most patients with Stage 3–5 CKD will die of cardiovascu-
lar complications prior to developing ESRD [6]. Several
studies in high-risk populations and community-based
studies have identified the level of kidney dysfunction as
an independent risk factor for cardiovascular outcomes
and all-cause mortality [7–13]. Currently, available data
concerning cardiovascular risk factors in CKD patients
are largely derived from retrospective analyses with lim-
ited biochemical analysis available of potential uremia-
related cardiovascular risk factors.
In ESRD patients, it is now well-established that
there is a high prevalence of acute-phase inflammation
and oxidative stress, both of which are associated with
the high rate of cardiovascular morbidity and mortality
[14–17]. Whether inflammation and oxidative stress are
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independent “uremia” associated cardiovascular risk fac-
tors that also apply to the CKD population is unclear.
Currently, there are few prevalence studies examining
biomarkers of oxidative stress and inflammation in the
larger population of patients with CKD. Given the high
prevalence of cardiovascular disease in the CKD pop-
ulation, we hypothesized that this population would
manifest an increase in biomarkers of inflammation and
oxidative stress, and that these biomarkers would in-
versely correlate with GFR. We therefore examined com-
monly utilized biomarkers of acute-phase inflammation
and oxidative stress status in a cohort of patients with
stage 3–5 CKD not receiving renal replacement therapy.
METHODS
Patient characteristics
The study subject population consisted of 60 consec-
utive patients followed at a CKD clinic who gave in-
formed consent to participate in a cross-sectional study.
The study protocol was approved by the Maine Medi-
cal Center IRB. Twenty-two of 60 patients were female
(37%), and the mean age was 67 ± 14 (range 32–91). GFR
was estimated using the MDRD prediction equation in
mL/min/1.73 m2 [170 × (creatinine)−0.999 × (age)−0.76 ×
(urea)−0.170 × (albumin)+0.318× 0.762 if female] [18]. The
range of estimated GFR was from 7 to 54 mL/min
(mean 27 mL/min, SD ± 11). Study subjects underwent
a detailed review of their medical history, and labora-
tory measurements consisting of biomarkers of oxidative
stress status and acute-phase inflammation at the time
of study enrollment. Etiology of chronic kidney disease
was determined by chart review. The etiologies consisted
of hypertensive nephrosclerosis (24 patients), diabetic
glomerulosclerosis (19 patients), glomerulonephritis
(4 patients), polycystic kidney disease (2 patients), reno-
vascular disease (4 patients), scleroderma (1 patient), re-
flux nephropathy (1 patient), renal dysplasia (1 patient),
sarcoidosis (1 patient), atheroembolic disease (1 patient),
obstructive uropathy (1 patient), and loss of renal mass
from malignancy (1 patient). Prevalent coronary vascu-
lar disease was defined by history of a revascularization
procedure (e.g., either a percutaneous coronary interven-
tion or coronary artery bypass grafting). Hypercholes-
terolemia was defined by charted diagnosis and/or the
use of statins or other anti-hypercholesterolemic medica-
tions. A healthy subject pool was utilized for comparison
of biomarkers of oxidative stress status and inflamma-
tion [N = 54 for C-reactive protein (CRP), N = 50 for
interleukin-6 (IL-6), N = 70 for thiols, N = 53 for car-
bonyls, and N = 48 for F2-isosprostanes]. Healthy sub-
jects were obtained from health care facility employees
and a local geriatric primary care practice. The mean age
of healthy subjects was 51.4 ± 1.7 years (range 22–93),
which was larger than the CKD population (P < 0.001).
Fifty-eight percent were female and 95% were Caucasian.
Informed consent was obtained prior to phlebotomy.
Blood sampling
For CRP measurements, blood was drawn into Vacu-
tainer (Becton-Dickinson, Franklin Lakes, NJ, USA)
serum separator tubes containing clot activator. Tubes
were kept at room temperature and centrifuged within
one hour of blood draw. For IL-6 and oxidative stress
biomarker measurements, blood was drawn into Vacu-
tainer tubes containing EDTA. Tubes were immediately
placed on ice, centrifuged, and kept at 4◦C until frozen.
Plasma and serum samples were stored at −70◦C until
analysis.
Plasma protein reduced thiol content
The assay for plasma protein reduced thiol content
measures the major source of reducing equivalents (or an-
tioxidant capacity) available in the plasma. Thiol groups
were assayed according to the method of Ellman [19] as
modified by Hu [20], as we have previously described
[21]. Briefly, 1 mL of buffer containing 0.1mol/L Tris,
1 mmol/L EDTA, pH 8.2, and 50 lL plasma was added
to cuvettes, followed by 50 lL 10 mmol/L 5′5′dithio-bis
(2-nitrobenzoic acid) (DTNB) in methanol. Blanks were
run for each sample, prepared as above, with the excep-
tion that there was no DTNB in the methanol. Following
incubation for 15 minutes at room temperature, sample
absorbance was read at 412 nm on a Lambda2 spec-
trophotometer (Perkin Elmer, Norwalk, CT, USA). Sam-
ple and reagent blanks are subtracted. The concentra-
tion of thiol groups was determined using the 5-thio-2-
nitrobenzoic acid (TNB) molar extinction coefficient of
14,100 mol/L−1 cm−1, and results are reported as micro-
moles per liter.
Plasma protein carbonyl group content
Plasma protein carbonyl content measures reactive
aldehyde content as an index of oxidative stress. Carbonyl
groups are measured using the Zentech PC Test Kit from
Zenith Technology (Dunedin, New Zealand). This kit fol-
lows the method outlined by Buss et al [22], as amended
by Winterbourn and Buss [23], which utilizes derivatiza-
tion of protein carbonyls in samples and oxidized protein
standards with dinitrophenylhydrazine (DNPH), fol-
lowed by enzyme-linked immunosorbent assay (ELISA)
with anti-DNP antibody as we have previously described
[21]. Standard ELISA techniques for labeling and visual-
izing labeled molecules were used. Absorbance was read
at 450 nm on an MRX microplate reader from Dynex
Technologies (Chantilly, VA, USA). A standard curve
was plotted and the carbonyl concentration of samples
was read off the curve.
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Table 1. Comparison of inflammatory and oxidative stress
biomarkers in CKD patients and healthy subjects
Healthy CKD
subjects patients P value
CRP mg/L 1.8 (0–28.6) 3.9 (0.6–28.4) 0.02
IL-6 pg/mL 2.1 (1.5–12.5) 6.4 (1.5–95.4) 0.001
Thiols lmol/L 415 (262–497) 303 (193–435) <0.001
Carbonyls nmol/ 0.029 (0–0.154) 0.061 (0.020–0.134) <0.001
mg protein
F2-isoprostanes 0.036 (0.019–0.179) 0.046 (0.025–0.156) <0.001
ng/mL
Abbreviations are: CRP, C-reactive protein; IL-6, interleukin-6; CKD, chronic
kidney disease. Data are given as medians, with range in parentheses.
Plasma-free F2-isoprostane content
F2-isoprostanes are lipid peroxidation products pro-
duced by free radical mediated non-enzymatic oxidation
of arachidonic acid. Free F2-isoprostanes esterified
to plasma lipids were quantified in plasma by gas
chromatography/negative-ion chemical ionization mass
spectrometry as we have described [24]. The precision
of the assay for free F2-isoprostanes was ± 6%, and the
accuracy was 96%. Data are expressed in ng/mL.
Inflammatory biomarkers
Plasma IL-6 cytokine concentrations were determined
by ELISA with kits from BioSource International
(Camarillo, CA, USA). Detection limit of the assay was
1.5 pg/mL. High sensitivity CRP was measured in serum
using nepholometry.
Statistics
Descriptive results are reported as medians and ranges.
Distribution of variables of interest were examined and
tested for normality using Shapiro-Wilk statistic. Because
these distributions departed significantly from normality,
nonparametric tests were used for bivariate comparisons,
including tests of differences in medians and Spearman’s
correlations. For comparisons of CKD patients and
healthy subjects and CKD patients by cardiovascular
risk factor status, data were analyzed using the Mann-
Whitney U test. Within the CKD population, Spearman
correlation coefficients were used to assess relationships
among GFR, markers of nutritional status, biomarkers
of inflammation, and oxidative stress status. Multiple lin-
ear regression was used to examine the relationship of
cardiovascular risk factors and CRP; because CRP was
skewed, the dependent variable was log transformed.
RESULTS
Biomarkers of inflammation and oxidative stress
status are increased in CKD patients compared
to healthy subjects
Table 1 demonstrates that levels of the inflammatory
markers CRP (P = 0.02) and IL-6 (P = 0.001) were sig-
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Fig. 1. The relationship between estimated glomerular filtration rate
and C-reactive protein. The coefficient of correlation is R = 0.03, P =
0.84.
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Fig. 2. The relationship between estimated glomerular filtration rate
and plasma interleukin-6 level. The coefficient of correlation is R = 0.08,
P = 0.54.
nificantly higher in CKD patients compared to healthy
subjects. Similarly, the plasma levels of protein-associated
carbonyl content (P < 0.001) and free F2-isoprostane con-
tent (P = 0.001) are significantly higher in CKD patients
compared to healthy subjects. Plasma protein–reduced
thiol content was significantly lower in CKD patients
compared to healthy subjects (P < 0.001).
Relationship of GFR to biomarkers of inflammation
and oxidative stress status in CKD patients
To examine the potential relationship between decre-
ment in GFR and acute-phase inflammation, the level
of GFR was compared to CRP and IL-6 levels in CKD
patients. Figures 1 and 2 demonstrate that there are no
significant correlations between GFR and levels of CRP
(R = 0.03, P = 0.84) or IL-6 (R = 0.08, P = 0.54). Sim-
ilarly, Figures 3, 4, and 5 demonstrate that there was no
significant correlation between GFR and the level of
plasma protein carbonyl content (R = 0.08, P = 0.56),
plasma F2-isoprostane content (R = 0.02, P = 0.89),
or plasma protein–associated free thiol content (R =
−0.14, P = 0.28). If patients receiving angiotensin- con-
verting enzyme inhibitors or angiotensin receptor block-
ers were excluded from the analysis, there was still no
significant correlation between any biomarker of oxida-
tive stress or inflammation and GFR (R = 0.16 and P =
0.68 for CRP, other data not shown).
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Fig. 3. The relationship between estimated glomerular filtration rate
and plasma protein carbonyl content. The coefficient of correlation is
R = 0.08, P = 0.56.
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Fig. 4. The relationship between estimated glomerular filtration rate
and plasma free F2-isoprostane content. The coefficient of correlation
is R = 0.02, P = 0.89.
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Fig. 5. The relationship between estimated glomerular filtration rate
and plasma protein reduced thiol content. The coefficient of correlation
is R = 0.14, P = 0.28.
Association of cardiovascular risk factors with inflamma-
tion and oxidative stress
Relationships between traditional cardiovascular risk
factors, cardiovascular therapeutics, and biomarkers of
inflammation and oxidative stress in this CKD cohort are
presented in Table 2. Levels of CRP correlate with age
(data not shown) and are significantly higher in patients
with known coronary vascular disease compared to the
remainder of CKD patients (P < 0.001). Of interest, lev-
els of CRP are significantly lower in patients for whom
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers are prescribed compared to patients
not receiving these types of medication (P < 0.05). Pa-
tients receiving statins also had significantly lower IL-6
levels (P < 0.05). The use of angiotensin inhibitors was
similar in patients with Stage 3 CKD (12/25, 48%) and
with Stage 4–5 CKD (12/35, 34%). Similarly, statin use
was similar in patients with Stage 3 CKD (14/25, 56%)
to patients with Stage 4–5 CKD (15/35, 43%). All plasma
biomarkers of oxidative stress status did not differ signif-
icantly between patients with or without known coronary
vascular disease or between patients receiving or not re-
ceiving angiotensin II inhibitors.
Given the novelty of the finding that the use of
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers were associated with lower CRP levels,
a multivariable regression analysis was conducted includ-
ing age, gender, diabetes mellitus, angiotensin II inhibitor
use, coronary artery disease, hypercholesterolemia, and
smoking. Additional models were constructed, control-
ling for GFR. In all models, the use of ACE inhibitors or
angiotensin receptor blockers was significantly negatively
associated with CRP (Table 3).
Diabetes mellitus and hypercholesterolemia are con-
sidered “traditional” risk factors for cardiovascular
disease. In this patient cohort, hypercholesterolemic pa-
tients exhibited an increase in biomarkers of oxidative
stress status, with significantly increased F2-isoprostane
content (P < 0.05), and lower plasma protein reduced
thiol content (P < 0.05) compared to patients without
a diagnosis of hypercholesterolemia. A trend toward a
difference in F2-isoprostane content was also observed
in patients on statins (who constitute a subset of hy-
percholesterolemic patients in this study) compared to
patients not receiving statins, which did not reach signif-
icance. Patients with diabetes mellitus have significantly
higher plasma protein carbonyl content (P < 0.05) and a
trend toward lower plasma protein reduced thiol content
(P = 0.07) compared to CKD patients without diabetes
mellitus, demonstrating a further increase in oxidative
stress in diabetic patients.
DISCUSSION
In this study, we have examined commonly utilized
biomarkers of inflammation and oxidative stress status
to examine a cohort of patients with stage 3–5 CKD not
receiving renal replacement therapy. Our hypothesis was
that these markers would negatively correlate with the
level of GFR and become more prominent at the very late
stages of CKD. In contrast to our original hypothesis, our
results demonstrate that increased oxidative stress and
inflammation are prevalent in patients with CKD well be-
fore the initiation of renal replacement therapy, but not
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Table 2. Association of cardiovascular risk factors with inflammation and oxidative stress biomarkers
Carbonyls F2 Lsoprostanes
IL-6 pg/mL CRP mg/L Thiols lmol/L nmol/mgprotein ng/mL
Diabetes mellitus
No (N = 31) 6.9 (1.5–95.4) 4.1 (0.3–28.4) 319 (221–435) 0.052 (0.020–0.110) 0.046 (0.030–0.156)
Yes (N = 29) 4.9 (1.5–30.5) 3.7 (0.6–25.9) 290 (193–386) 0.080 (0.027–0.134)a 0.047 (0.025–0.145)
Tobacco use
No (N = 55) 6.3 (1.5–95.4) 3.7 (0.6–28.4) 301 (193–435) 0.064 (0.020–0.134) 0.046 (0.025–0.156)
Yes (N = 5) 15.5 (4.5–30.5) 4.3 (3.3–6.7) 323 (232–334) 0.052 (0.050–0.080) 0.062 (0.039–0.144)
Known CVD
No (N = 41) 5.1 (1.5–30.5) 3.1 (0.6–11.3) 306 (223–435) 0.060 (0.020–0.134) 0.046 (0.025–0.156)
Yes (N = 19) 11.8 (1.5–95.4)a 8.7 (0.6–28.4)b 298 (193–385) 0.064 (0.030–0.110) 0.046 (0.026–0.072)
Hypercholesterolemia
No (N = 16) 6.7 (1.5–23.3) 3.1 (0.6–28.4) 330 (221–435) 0.051 (0.020–0.095) 0.042 (0.026–0.070)
Yes (N = 44) 5.0 (1.5–95.4) 4.5 (0.6–25.9) 300 (193–386) 0.063 (0.025–0.134) 0.050 (0.025–0.156)a
ACE inhibitor use
No (N = 36) 6.4 (1.5–30.5) 6.2 (0.6–28.4) 319 (193–421) 0.058 (0.020–0.110) 0.046 (0.026–0.156)
Yes (N = 24) 5.5 (1.5–95.4) 2.2 (0.6–24.1)a 291 (223–435) 0.074 (0.027–0.134) 0.051 (0.025–0.145)
Statin use
No (N = 31) 9.8 (1.5–95.4) 4.2 (0.6–28.4) 301 (193–435) 0.064 (0.020–0.110) 0.042 (0.026–0.156)
Yes (N = 29) 4.5 (1.5–27.5)a 3.1 (0.6–25.9) 305 (223–386) 0.060 (0.027–0.134) 0.051 (0.025–0.145)
aP < 0.05
bP < 0.001
Table 3. Multivaviate regression analysis of angiotensin inhibitors
and C- reactive protein levels
Coefficient Standard error P
ACE alone −0.84 0.23 0.0006
ACE + demographicsa −0.71 0.21 0.001
ACE + demographics −0.60 0.24 0.01
+ cardiac risk factorsb
ACE + demographics −0.75 0.23 0.002
+ cardiac risk factors + GFR
ACE is angiotensin-converting enzyme.
aDemographics, age, gender.
bCardiac risk factors, known CAD, diabetes, hypercholesterolemia, smoking.
closely correlated with estimates of GFR. In addition,
we observed a positive correlation between the inflam-
matory biomarkers CRP and IL-6 and the presence of
known cardiovascular disease and a negative correlation
with angiotensin inhibitor and statin use.
The most notable finding in this study is that there does
not appear to be a close relationship between GFR and
the extent to which increased inflammation and oxida-
tive stress are present in CKD patients. This is in con-
tradistinction to many “classical” uremic toxins, where
there is a close inverse relationship between plasma con-
centration of the toxin and the GFR [25]. A potential
explanation for the limited correlation of biomarkers
of oxidative stress and inflammation with GFR may be
that many of the solutes used as biomarkers undergo
renal clearance primarily via renal tubular metabolism
rather than glomerular filtration. For example, aldehyde-
modified proteins (as detected in the carbonyl assay)
likely undergo metabolism via aldehyde dehydrogenase,
an enzyme associated with tubular epithelial cells [26, 27].
Similarly, the redox status of amino acid–containing low-
molecular-weight thiols are extensively and selectively
modified by proximal tubular metabolism and transport
[28–30]. Thus, plasma protein thiol oxidation and plasma
protein carbonyl content may be largely regulated by
proximal tubular function and not glomerular filtration.
Inflammation is a common feature of ESRD; how-
ever, there have been few studies examining biomark-
ers of acute-phase inflammation in patients with less
advanced kidney disease. Furthermore, the extent to
which GFR is related to biomarkers of inflammation is
controversial. Several studies have associated changes in
GFR with biomarkers of inflammation, particularly in
patients with advanced disease [31–34]. In baseline data
from the Cardiovascular Health Study, levels of CRP and
IL-6 were found to be significantly higher in patients with
renal insufficiency compared to patients with normal kid-
ney function [35]. In a recent community-based cross-
sectional study, increased CRP was found to associate
with decreased GFR. However, in a recent study utilizing
the Modification of Diet in Renal Disease (MDRD) base-
line data, serum CRP levels were found not to correlate
with either GFR or disease progression [36]. The find-
ings in the present study would support these data that
elevations in biomarkers of inflammation such as CRP
and IL-6 are present earlier in the course of kidney dis-
ease than previously recognized, but would suggest they
are not necessarily well correlated with GFR.
Oxidatively modified amino acids and plasma proteins
can serve as important in vivo biomarkers of oxidative
stress [37]. In this study we examined plasma protein
thiol group oxidation and carbonyl content as in vivo
biomarkers of oxidative stress. The protein carbonyl as-
say measures reactive aldehydes formed as end products
of a variety of oxidative reactions. The potential sig-
nificance of elevated aldehyde concentrations is clearly
demonstrated by their prominent role in the pathogen-
esis of atherosclerosis [38, 39]. Reduced extracellular
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thiols measured in this study as plasma protein reduced
thiol content are an important component in antioxidant
defense with high relevance to cardiovascular disease. In
an earlier study, we demonstrated a similar increase in
plasma protein carbonyl content and decreased plasma
protein reduced thiol content in a small cohort of patients
with advanced CKD compared to healthy subjects [21].
The present study extends these findings in a larger cohort
by demonstrating increased plasma protein oxidation is a
nearly universal finding in patients with stage 3–5 CKD,
without being closely related to estimated GFR. In this
study we also examined plasma F2-isoprostane content as
a lipid biomarker of oxidative stress, and demonstrated
elevated levels in CKD patients compared to healthy sub-
jects. Measurement of F2-isoprostanes are considered a
reliable indicator of lipid peroxidation and have previ-
ously been demonstrated by our group and others to be
elevated in maintenance hemodialysis patients [40, 41].
Although increased oxidative stress is increasingly rec-
ognized as an important metabolic accompaniment to
ESRD, there have been remarkably few studies utilizing
biomarkers of oxidative stress in the CKD population.
Annuk et al reported on 37 patients with a mean crea-
tinine clearance of 25 mL/min and demonstrated alter-
ations in lipid peroxidation end products and glutathione
content in patients with CKD. Of note, these investiga-
tors correlated alterations in oxidative stress status with
endothelial dysfunction in the CKD patient cohort [42].
Bolton et al examined 17 patients with chronic kidney dis-
ease (GFR <50 mL/min) and demonstrated increased au-
toantibodies to oxidized low-density lipoprotein (LDL)
[43]. Mezzano et al examined 64 patients with advanced
CKD and demonstrated increases in lipid peroxidation
and advanced oxidation protein products (AOPP) [44].
Witko-Sarsat et al examined a cohort of 162 uremic pa-
tients, demonstrating elevations in AOPP and a close re-
lationship of AOPP accumulation to GFR [45]. These
studies suggest that the myriad of oxidative stress changes
associated with ESRD are also prevalent in the CKD pop-
ulation.
An interesting finding in this study is that patients
with CKD being treated with angiotensin-converting en-
zyme inhibitors or angiotensin receptor blockers appear
to have lower CRP levels than patients not receiving these
therapeutic agents. The renin-angiotensin system is an
important regulator of blood pressure and fluid and elec-
trolyte homeostasis and plays a central role in the pro-
gression of glomerulosclerosis, nephrosclerosis, and renal
interstitial fibrosis. As a consequence, angiotensin II in-
hibitors are frequently used in an attempt to arrest the
progression of renal disease and to reduce proteinuria.
Many of the effects of angiotensin II signaling on target
tissues are mediated via increased production of reac-
tive oxygen species through activation of the NAD(P)H
oxidases [46, 47]. Several recent studies have also demon-
strated that the use of angiotensin II inhibitors may have
potent anti-inflammatory effects [48–50]. A single previ-
ous study of patients with advanced CKD noted that pa-
tients receiving ACE inhibitors or angiotensin receptor
blockers (ARBs) had lower plasma tumor necrosis fac-
tor alpha levels and better nutritional status relative to
patients not treated with ACE inhibitors [51]. This study
suggests that the beneficial effects of angiotensin inhibi-
tion may operate through anti-inflammatory mechanisms
in the CKD population. The finding of an association
between ACE inhibitors and/or ARBs and lower CRP
levels in the present observational study cannot be uti-
lized to make causal inferences, and should be interpreted
with caution, given the cross-sectional study design and
relatively small sample size. This potential relationship
should be examined prospectively in controlled studies.
Of note, a significant relationship between statin use and
CRP levels was not identified in this study (even though
the relationship between statin use and IL-6 levels was
significant), despite previous studies in other patient pop-
ulations that have observed such a relationship. However,
a significant association may have been missed due to
sample size in the present study, as the magnitude of pre-
viously observed effects of statins on CRP have been rel-
atively small (approximately 15%) [52–54]. Similarly, an
association between the levels of oxidant stress biomark-
ers and cardiovascular disease may have been missed due
to sample size. A weakness in the present study is its cross-
sectional, observational nature, as well as the relatively
small sample size. In an observational study, it is possible
to demonstrate associations between CKD and the pres-
ence of increased oxidative stress and inflammation, but
not to determine causal relationships. Additionally, be-
cause of the relatively small sample size, there may be re-
lationships between clinical parameters (such as etiology
of renal disease, gender, race, age, nutritional status, and
conventional cardiovascular risk factors), inflammation,
and oxidative stress in the CKD population that were not
determined due to type B statistical errors.
CONCLUSION
The present study is useful in its clear-cut demon-
stration of excess inflammation and oxidative stress in
the CKD cohort and in the lack of a demonstrated
strong correlation with the degree of GFR. This provides
hypothesis-driven support for prospective longitudinal
observational and randomized clinical trials examining
oxidative stress and inflammation in the CKD popula-
tion, as well as potential cardiovascular consequences.
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